Haris Jamil
Profile
Haris Jamil worked as a Principal at Bristol Myers Squibb Co., NeoPharm, Inc., and OVATION Pharmaceuticals, Inc. He also worked as the Vice President-NanoStem Cell Division at NanoInk, Inc. Dr. Jamil holds a doctorate degree from the University of London.
Former positions of Haris Jamil
| Companies | Position | End |
|---|---|---|
OVATION Pharmaceuticals, Inc.
 OVATION Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OVATION Pharmaceuticals, Inc. develops, manufactures and markets pharmaceuticals. It focuses on central nervous system, hematology or oncology and hospital-based therapies. The company was founded by Jeffrey S. Aronin in 2000 and is headquartered in Deerfield, IL. | Corporate Officer/Principal | - |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
NeoPharm, Inc.
 NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | Corporate Officer/Principal | - |
NanoInk, Inc.
 NanoInk, Inc. Industrial MachineryProducer Manufacturing NanoInk, Inc. is an emerging growth technology company specializing in nanometer-scale manufacturing and applications development for the life sciences, engineering, pharmaceutical, and education industries. Using Dip Pen Nanolithography® (DPN®), a patented and proprietary nanofabrication technology, scientists are enabled to rapidly and easily create micro-and nanoscale structures from a variety of materials on a range of substrates. This low cost, easy to use and scalable technique brings sophisticated nanofabrication to the laboratory desktop. Headquartered in the Illinois Science + Technology Park, north of Chicago, NanoInk currently has over 250 patents and applications filed worldwide and licensing agreements with Northwestern University, Stanford University, University of Strathclyde, University of Liverpool, California Institute of Technology and the University of Illinois at Urbana-Champaign. | Corporate Officer/Principal | - |
Training of Haris Jamil
| University of London | Doctorate Degree |
Experiences
Positions held
Linked companies
| Listed companies | 1 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Private companies | 3 |
|---|---|
NanoInk, Inc.
NanoInk, Inc. Industrial MachineryProducer Manufacturing NanoInk, Inc. is an emerging growth technology company specializing in nanometer-scale manufacturing and applications development for the life sciences, engineering, pharmaceutical, and education industries. Using Dip Pen Nanolithography® (DPN®), a patented and proprietary nanofabrication technology, scientists are enabled to rapidly and easily create micro-and nanoscale structures from a variety of materials on a range of substrates. This low cost, easy to use and scalable technique brings sophisticated nanofabrication to the laboratory desktop. Headquartered in the Illinois Science + Technology Park, north of Chicago, NanoInk currently has over 250 patents and applications filed worldwide and licensing agreements with Northwestern University, Stanford University, University of Strathclyde, University of Liverpool, California Institute of Technology and the University of Illinois at Urbana-Champaign. | Producer Manufacturing |
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | Health Technology |
OVATION Pharmaceuticals, Inc.
OVATION Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OVATION Pharmaceuticals, Inc. develops, manufactures and markets pharmaceuticals. It focuses on central nervous system, hematology or oncology and hospital-based therapies. The company was founded by Jeffrey S. Aronin in 2000 and is headquartered in Deerfield, IL. | Health Technology |
- Stock Market
- Insiders
- Haris Jamil
